# SPECIALTY GUIDELINE MANAGEMENT

## **ELAHERE** (mirvetuximab soravtansine-gynx)

#### **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### **FDA-Approved Indication**

Elahere is indicated for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

All other indications are considered experimental/investigational and not medically necessary.

#### **II. DOCUMENTATION**

Submission of the following information is necessary to initiate the prior authorization review:

Documentation of testing or laboratory results confirming folate receptor-alpha status, where applicable.

#### III. CRITERIA FOR INITIAL APPROVAL

### Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Authorization of 12 months may be granted for treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer when all of the following criteria are met:

- 1. Member has folate receptor-alpha positive disease
- 2. Member has platinum-resistant disease
- 3. Member has received at least one prior systemic therapy

#### IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

#### V. REFERENCES

1. Elahere [package insert]. Waltham, MA: ImmunoGen, Inc.; November 2022.

Elahere 5670-A SGM P2022.docx

© 2022 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

